Genomic medicine company Chroma Medicine Inc announced on Thursday the appointment of Melissa J Moore, PhD to its board of directors.
Dr Moore is currently a board director and Scientific Advisory Board member for multiple biotechnology companies. She previously served as chief scientific officer, Platform Research, at Moderna Inc (NASDAQ:MRNA).
Dr Moore co-founded the RNA Therapeutics Institute at the University of Massachusetts Medical School and was a professor of Biochemistry & Molecular Pharmacology, Eleanor Eustis Farrington Chair in Cancer Research, and a long-time Investigator at the Howard Hughes Medical Institute.
Catherine Stehman-Breen, M.D., Chroma CEO, said: "Melissa brings decades of experience directing RNA research and drug development at leading pharma companies and in academia. Her deep knowledge will benefit us as we advance our platform of highly potent and durable epigenetic editors to patients, enabling a new class of genomic medicines."
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
Oncosure introduces Rapid Cancer Screening Test
Bayer and NextRNA collaborate on LncRNA-targeting therapeutics
GSK welcomes Delaware Supreme Court review of Zantac litigation
Fusion Antibodies expands collaboration with US National Cancer Institute
Telix Pharmaceuticals submits TLX101-CDx NDA to US FDA
Astellas initiates Phase 3 study for fezolinetant in breast cancer patients
Cantargia updates clinical trial timelines for nadunolimab
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation